Mariana Oncology Inc. CEO Simon Read believes that one of the reasons his company was able to raise the $175m series B venture capital round announced on 7 September was its differentiated approach to drug development in the increasingly crowded radiopharmaceutical space. While other radiopharmaceutical firms may source different parts of their molecules from outside sources or outsource their manufacturing, Mariana keeps all parts of the process in-house.
With $175m, Mariana Will Take First Precision Radiopharmaceutical Into The Clinic
Firm Raised $75m Series A In Late 2021 As Curie
Mariana Oncology closed a $175m series B venture capital round to fund its first clinical trial, for MC-339 in small-cell lung cancer, as well as its manufacturing and pipeline-building activities.
